Epilepsy Research
Volume 22, Issue 2 , Pages 65-95 , October 1995

Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research

  • Jan Vermeulen
    • ,
  • Albert P. Aldenkamp

      Affiliations

    • Corresponding Author InformationCorresponding author. ‘Meer & Bosch’ Epilepsy Centre, Achterweg 5, P.O. Box 21, 2100 AA Heemstede, The Netherlands. Tel.: (0)23-339060; fax: (0)23-294324 or (0)23-289412.

Received 30 April 1995 ,Accepted 22 July 1995.

References 

  1. Reynolds EH. Chronic antiepileptic toxicity: A review. Epilepsia. 1975;16:319–352
  2. Dodrill CB. Behavioral effects of antileptic drugs. In: 2nd edn..  Smith D,  Treiman D,  Trimble M editor. Advances in Neurology. Vol. 55:New York: Raven Press; 1991;p. 213–224
  3. Meador KJ, Loring DW. Cognitive effects of antiepileptic drugs. In:  Devinski O,  Theodore W editor. Epilepsy and Behavior. New York: Wiley-Liss; 1991;p. 151–170
  4. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1977;
  5. Evans RW, Gualtieri CT. Carbamazepine: A neuropsychological and psychiatric profile. Clin. Neuropharmacol. 1985;8(3):221–241
  6. Novelly RA, Schwartz MM, Mattson RH, et al.  Behavioral toxicity associated with antiepileptic drugs: Concepts and methods of assessment. Epilepsia. 1986;27(4):331–340
  7. Parnas J, Flachs H, Gram L. Psychotropic effect of antiepileptic drugs. Acta Neurol. Scand. 1979;60:329–343
  8. Parnas J, Gram L, Flachs H. Psychopharmacological aspects of antiepileptic treatment. Prog. Neurobiol. 1980;15:119–138
  9. Smith DB. Cognitive effects of antiepileptic drugs. In: 2nd edn..  Smith D,  Treiman D,  Trimble M editor. Advances in Neurology. Vol. 55:New York: Raven Press; 1991;p. 197–212
  10. Trimble MR. Anticonvulsant drugs and psychosocial development: Phenobarbitone, sodium valproate, and benzodiazepines. In:  Morselli PL,  Pippenger CE,  Penry JK editor. Antiepileptic Drug Therapy in Pediatrics. New York: Raven Press; 1983;p. 201–217
  11. Trimble MR. Anticonsulvant drugs and cognitive function: A review of the literature. Epilepsia. 1987;28(Suppl. 3):37–45
  12. Trimble MR. Anticonvulsant drugs: Mood and cognitive function. In:  Trimble MR,  Reynolds EH editor. Epilepsy, Behavior and Cognitive Function. Chichester: John Wiley & Sons; 1987;p. 135–145
  13. Trimble MR, Cull C. Children of school age: The influence of antiepileptic drugs on behavior and intellect. Epilepsia. 1988;29(Suppl. 3):S15–S19
  14. Trimble MR, Thompson PJ. Memory, anticonvulsant drugs and seizures. Acta Neurol. Scand. 1981;63:31–41
  15. Trimble MR, Thompson PJ. Anticonvulsant drugs, cognitive function and behaviour. Epilepsia. 1983;24(Suppl. 1):S55–S63
  16. Trimble MR, Thompson PJ. Sodium valproate and cognitive function. Epilepsia. 1984;25(Suppl. 1):60–64
  17. Trimble MR, Thompson PJ. Anticonvulsant drugs, cognitive function and behaviour. In:  Ross E,  Reynolds EH editor. Paediatric Perspectives on Epilepsy. Chichester: John Wiley & Sons; 1985;p. 141–148
  18. Trimble MR, Thompson PJ, Huppert F. Anticonvulsant drugs and cognitive abilities. In:  Canger R,  Angeleri F,  Penry JK editor. Advances in Epileptology. New York: Raven Press; 1980;p. 199–204
  19. Sacks HS, Berrier J, Reitman D, et al.  Meta-analyses of randomized controlled trials. N. Engl. J. Med. 1987;316(8):450–455
  20. Massagli TL. Neurobehavioural effects of phenytoin, carbamazepine, and valproic acid: Implications for use in traumatic brain injury. Arch. Phys. Med. Rehabil. 1995;72:219–226
  21. Camfield CS, Chaplin S, Doyle AB, et al.  Side effects of phenobarbital in toddlers: Behavior and cognitive aspects. J. Pediatr. 1979;95:361–365
  22. Wolf SM, Forsythe A, Stunden AA, et al.  Long-term effect of phenobarbital on cognitive function in children with febrile convulsions. Pediatrics. 1981;68(6):820–823
  23. Farwell JR, Lee YJ, Hirtz DG, et al.  Phenobarbital for febrile seizures—Effects on intelligence and on seizure recurrence. New Engl. J. Med. 1990;322(6):364–369
  24. Dodrill CB, Temkin NR. Motor speed is a contaminating factor in evaluating the ‘cognitive’ effects of phenytoin. Epilepsia. 1989;30:453–457
  25. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: A reanalysis. Neurology. 1991;41:141–143
  26. Dodrill CB. Diphenylhydantoin serum levels, toxicity and neuropsychological performance in patients with epilepsy. Epilepsia. 1975;16:593–600
  27. Dodrill CB, Troupin AS. Psychotropic effects of carbazepine in epilepsy: A double-blind comparison with phenytoin. Neurology. 1977;27:1023–1028
  28. Meador KJM, Loring DW, Abney OL, et al.  Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia. 1993;34(1):153–157
  29. Tonnby B, Nilsson H, Aldenkamp AP, et al.  Withdrawal of antiepileptic medication in children—Correlation of cognitive function and plasma concentration—The multicentre ‘Holmfrid’ study. Epilepsy Res. 1994;19:141–152
  30. Meador KJM, Loring DW, Allen ME, et al.  Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology. 1991;41:1537–1540
  31. Aldenkamp AP, Alpherts WCJ, Blennow G, et al.  Withdrawal of antiepileptic medication—Effects on cogntive function in children—The results of the multicentre ‘Holmfrid’ study. Neurology. 1993;43(1):41–51
  32. Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia. 1982;33:531–534
  33. Thompson PJ, Trimble MR. Further studies on anticonvulsant drugs and seizures. Acta Neurol. Scand. 1980;60:51–58
  34. Ideström CM, Schalling D, Carlquist U, et al.  Behavioral and psychological studies: Acute effects of diphenylhydantoin in relation to plasma levels. Psychol. Med. 1972;2:111–120
  35. Houghton GW, Latham AN, Richens A. Differences in the central actions of phenytoin and phenobarbitone in man, measured by critical flicker fusion treshold. Eur. J. Clin. Pharmacol. 1973;6:57–60
  36. Boxer CM, Herzberg JL, Scott DF. Has sodium valproate hypnotic effects?. Epilepsia. 1976;17:367–370
  37. Cohen AF, Crowley LAD, Land G, et al.  Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br. J. Clin. Pharmacol. 1985;20:619–629
  38. MacPhee GJA, Goldie C, Roulston D, et al.  Effect of carbamazepine on psychomotor performance in naive subjects. Eur. J. Clin. Pharmacol. 1986;30:37–42
  39. Saletu B, Grunberger J, Linzmayer L, et al.  Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor. Int. J. Psychophysiol. 1986;4:63–80
  40. Tedeschi G, Casucci G, Allocca S. Computer analysis of saccadic eye movements: Assessment of two different carbamazepine formulations. Eur. J. Clin. Pharmacol. 1989;37:513–516
  41. Meyden CHvan der, Bartel PR, Sommers DK, et al.  Effect of acute doses of controlled-release carbamazepine on clinical, psychomotor, electrophysiological and cognitive parameters of brain function. Epilepsia. 1992;33(2):335–342
  42. Zaccara C, Gangemi PF, Messori A, et al.  Effects of oxcarbazepine and carbamazepine on the central nervous system: Computerized analysis of saccadic and smooth pursuit eye movements. Acta. Neurol. Scand. 1992;85:425–429
  43. Stephens JH, Schaffer JW, Brown CC. A controlled comparison of the effect of diphenylhydantoin and placebo on mood and psychomotor functioning in normal volunteers. J. Clin. Pharmacol. 1974;14:543–551
  44. Smith WL, Lowrery JB. Effects of diphenylhydantoin on mental abilities in the elderly. J. Am. Geriatr. Soc. 1975;23:207–211
  45. Thompson PJ, Huppert F, Trimble MR. Anticonvulsant drugs, cognitive function and memory. Acta Neurol. Scand. 1980;23:207–211
  46. Thompson PJ, Huppert FA, Trimble MR. Phenytoin and cognitive functions: Effects on normal volunteers and implications for epilepsy. Br. J. Clin. Psychol. 1981;20:155–162
  47. Thompson PJ, Trimble MR. Sodium valproate en cognitive functioning in normal volunteers. Br. J. Clin. Pharmacol. 1981;12:819–824
  48. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur. J. Clin. Pharmacol. 1993;44(6):529–533
  49. Stevens J. Applied Multiuariate Analysis for the Social Sciences. Hillsdale: Lawrence Erlbaum Associates; 1992;
  50. Kulig BM. The evaluation of the behavioral effects of antiepileptic drugs in animals and man. In:  Kulig BM,  Meinardi H,  Stores G editor. Epilepsy and Behauior. Lisse: Swets & Zetlinger; 1980;
  51. Dodrill CB, Wilensky AJ. Neuropsychological abilities before and after 5 years of stable antiepileptic drug therapy. Epilepsia. 1992;33(2):327–334
  52. Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms: A preliminary report. Br. J. Psychiatry. 1974;124:440–445
  53. Dekaban AS, Lehman EJB. Effects of different dosages of anticonvulsant drugs on mental performance in patients with chronic epilepsy. Acta Neurol. Scand. 1975;52:319–330
  54. Matthews CG, Harley JP. Cognitive and motorsensory performances in toxic and nontoxic epileptic subjects. Neurology. 1975;25:184–188
  55. Sommerbeck KW, Theilgaard A, Rasmussen KE. Valproate sodium: Evaluation of so-called psychotropic effect. A controlled study. Epilepsia. 1977;18:159–162
  56. Wilensky AJ, Ojemann LM, Temkin NR, et al.  Clorazepate and phenobarbital as antiepileptic drugs: A double-blind study. Neurology. 1981;31(10):1271–1276
  57. Thompson PJ, Trimble MR. Anticonvulsant serum levels; relationship to impairments of cognitive functioning. J. Neurol. Neurosurg. Psychiatry. 1983;46:227–233
  58. Corbett JA, Trimble MR, Nichol TC. Behavioral and cognitive impairments in children with epilepsy: The long-term effects of anticonvulsant therapy. J. Am. Acad. Child Psychiatry. 1985;24:17–23
  59. Ludgate J, Keating J, O'Dwyer R, et al.  An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neur. Scand. 1985;71:448–452
  60. Berent S, Sackellares JC, Giordani B, et al.  Zonisamide (CI-912) and cognition: Results from preliminary study. Epilepsia. 1987;28(1):61–67
  61. Durwen HF, Elger CE, Helmstaedter C, et al.  Circumscribed improvement of cognitive performance in temporal lobe epilepsy patients with intractable seizures following reduction of anticonvulsants medication. J. Epilepsy. 1989;2:147–153
  62. Prevey ML, Mattson RH, Cramer JA. Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. Neurology. 1989;39:1640–1641
  63. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine and valproate on cognitive function. Epilepsia. 1990;31(5):584–591
  64. Rijckevorsel-Harmant Kvan, Flahaut D, Harman J, et al.  Event-related potentials and cognitive functions in epileptic treated patients. Clin. Electroencephalogr. 1990;21(2):67–73
  65. Durwen HF, Hufnagel A, Elger CE. Anticonvulsant drugs affect particular steps of verbal memory processing—An evaluation of 13 patients with intractable complex partial seizures of left temporal lobe origin. Neuropsychologia. 1992;30(7):623–631
  66. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia. 1992;33(1):128–134
  67. McKee PJW, Blackclaw J, Butler E, et al.  Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 1992;11:193–198
  68. May TW, Bulmahn A, Wohlhueter M, et al.  Effects of withdrawal of phenytoin on cognitive and psychomotor functions in hospitalized epileptic patients on polytherapy. Acta Neurol. Scand. 1992;86(2):165–170
  69. Pieters MSM, Jennekens-Schinkel A, Stijnen Th, et al.  Carbamazepine (CBZ) controlled release compared with conventional CBZ: A controlled study of attention and vigilance in children with epilepsy. Epilepsia. 1992;33:1137–1144
  70. Gillham RA, Blacklaw J, McKee PJW, et al.  Effects of vigabatrin on sediation and cognitive function in patients with refractory epilepsy. J. Neurol. Neurosurg. Psychiatry. 1993;56:1271–1275
  71. Smith D, Baker G, Davies G, et al.  Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34(2):312–322
  72. Dodrill CB, Arnett JL, Sommerville KW, et al.  Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology. 1993;43:2501–2507
  73. Chataway J, Fowler A, Thompson PJ, et al.  Discontinuation of clonazepam in patients with active epilepsy. Seizure. 1993;2:295–300
  74. Durwen HF, Elger CE. Verbal learning differences in epileptic patients with left and right temporal lobe fociA pharmacologically induced phenomenon?. Acta Neurol. Scand. 1993;87:1–8
  75. Mitchell WG, Zhou Y, Chavez JM, et al.  Effects of antiepileptic drugs on reaction time, attention and impulsivity in children. Pediatrics. 1993;91(1):101–105
  76. McKee PJW, Blacklaw J, Forrest G, et al.  A doubleblind placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. J. Clin. Pharmacol. 1994;37:27–32
  77. Reynolds EH. Phenytoin: Toxicity. In:  Levy RH,  Dreifuss FE,  Mattson RH, et al. editor. Antiepileptic Drugs. New York: Raven Press; 1989;p. 241–256
  78. Butlin AT, Danta G, Cook ML. Anticonvulsants, folic acid and memory dysfunction in epileptics. Clin. Exp. Neurol. 1985;20:57–62
  79. Andrewes DG, Tomlinson L, Elwes RDC, et al.  The influence of carbamazepine and phenytoin on memory and other aspects of cognitive function in new referrals with epilepsy. Acta Neurol. Scand. 1984;69(S.99):23–30
  80. Andrewes DG, Bullen JG, Tomlinson L, et al.  A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia. 1986;27:128–134
  81. Brodie MJ, McPhail E, MacPhee GJA, et al.  Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. Eur. J. Clin. Pharmacol. 1987;31:655–660
  82. Gillham RA, Williams N, Widmann KD, et al.  Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J. Neurosurg. Psychiatry. 1988;51:929–933
  83. Gillham RA, Williams N, Weidmann KD, et al.  Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res. 1990;7:219–225
  84. Gillham RA, Read CL, McKee PJW, et al.  Cognitive function in adult epileptic patients on long-term sodium valproate. In: Epilepsy. New York: Demos Publications; 1991;p. 205–210
  85. Bigarella MM, Maeder MJ, Doro MP, et al.  Cognitive function of epileptic patients on monotherapy with phenobarbitone and healthy controls. Arq. Neuro-Pslquiatr. 1991;49(2):136–141
  86. Bittencourt PR, Mader MJ, Bigarella MM, et al.  Cognitive functions, epileptic syndromes and antiepileptic drugs. Arq. Neuro-Psiquiatr. 1992;50(1):24–30
  87. Verma NP, Yusko MJ, Greiffenstein MF. Carbamazepine offers no psychotropic advantage over phenytoin in adult epileptic subjects. Seizure. 1993;2:53–56
  88. Aldenkamp AP, Alpherts WCJ, Diepman L, et al.  Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res. 1994;19:37–43
  89. Cook D, Campbell DT. Quasi-Experimentation: Design & Analysis Issues for Field Settings. Boston: Houghton Mifflin Company; 1979;
  90. Dodrill CB. Problems in the assessment of cognitive effects of antiepileptic drugs. Epilepsia. 1992;33(Suppl. 6):S29–S32
  91. Kirk RE. Experimental Design: Procedures for the Behavioral Sciences. Belmont: Wadsworth Inc; 1982;
  92. Anastasi A. Differential Psychology: Individual and Group Differences in Behavior. New York: The Macmillan Company; 1958;
  93. Browne TR, Dreifuss FE, Dyken PR, et al.  Ethosuximide in the treatment of absence (petit mal) seizures. Neurology. 1975;25:515–524
  94. Gannaway DJ, Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. Br. J. Clin. Pharmacol. 1981;12:833–839
  95. Butlin AT, Danta G, Cook ML. Anticonvulsant effects on the memory performance of epileptics. Clin. Exp. Neurol. 1984;20:27–35
  96. Wilensky AJ, Friel PN, Ojemann LM, et al.  Zonisamide in epilepsy: A pilot study. Epilepsia. 1985;26:212–220
  97. Aldenkamp AP, Alpherts WCJ, Moerland MC, et al.  Controlled release carbamazepine: Cognitive side-effects in patients with epilepsy. Epilepsia. 1987;28:507–514
  98. Mitchell WG, Chaves JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia. 1987;28:56–60
  99. Smith DB, Mattson RH, Cramer JA, et al.  Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin and primidone. Epilepsia. 1987;28(Suppl. 3):S50–S58
  100. MacLeod CM, Dekaban AS, Hunt E. Memory impairment in epileptic patients: Selective effects of phenobarbital concentration. Science. 1978;202:1102–1104
  101. MacPhee GJA, MacPhail EM, Butler E, et al.  Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients. Eur. J. Clin. Pharmacol. 1986;31:195–199
  102. Amman MG, Werry JS, Paxton JW, et al.  Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration and diagnosis. Epilepsia. 1987;28:115–124
  103. O'Dougherty M, Wright FS, Cox S, et al.  Carbamazepine plasma concentration. Relationship to cognitive impairment. Arch. Neurol. 1987;44:863–867
  104. Amman MG, Werry JS, Paxton JW, et al.  Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type and time of medication. Epilepsia. 1990;31:51–60
  105. Reinvang I, Bjarveit S, Johannessen SI, et al.  Cognitive function and time-of-day variation in serum carbamazepine concentration in epileptic patients treated with monotherapy. Epilepsia. 1991;32:116–121
  106. Brouwer OF, Pieters MSM, Bakker AM, et al.  Conventional and controlled release valproate in children with epilepsy: A cross-over study comparing plasma levels and cognitive performance. Epilepsy Res. 1992;13:245–253
  107. Larkin JG, McKee PJW, Brodie MJ. Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients. Br. J. Clin. Pharmacol. 1992;33:111–114
  108. Rönnberg J, Samuelsson S, Söderfeldt K. Memory effects following carbamazepine monotherapy in patients with complex partial epilepsy. Seizure. 1992;1:247–253
  109. McKee PJW, Blacklaw J, Carswell A, et al.  Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. Br. J. Clin. Pharmacol. 1993;36:257–261
  110. Amman MG, Werry JS, Paxton JW, et al.  Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type and time of medication. Epilepsia. 1994;35:172–180
  111. Vining EP, Mellitis ED, Dorsen MM, et al. , Freeman JM  Psychologic and behavioral effects of antiepileptic drugs in children: A double-blind comparison between phenobarbital and valproic acid. Pedriatics. 1987;80(2):165–174
  112. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al.  Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol. Scand. 1990;81:504–506
  113. Meador KJM, Loring DW, Huh K, et al.  Comparative cognitive effects of anticonvulsants. Neurology. 1990;40:391–394
  114. Forsythe I, Butler R, Berg I, et al.  Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev. Med. Child Neurol. 1991;33:524–534
  115. Aikiae M, Kaelviaeinen R, Sivenius J, et al.  Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: One year follow-up. Epilepsy Res. 1992;11(3):199–203
  116. Bittencourt PR, Antoniuk SA, Bigarella MM, et al.  Carbamazepine and phenytoin in epilepsies refractory to bartiburates: Efficacy, toxicity and mental function. Epilepsy Res. 1993;16:147–155
  117. Helmstaedter C, Wagner G, Elger CE. Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy. Seizure. 1993;2:125–130
  118. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: Results of a single-blind randomized comparative study. Epilepsia. 1994;35:381–390
  119. Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurol. Scand. 1994;89:81–86
  120. Gallassi R, Lorusso S, Stracciari A, et al.  Withdrawal of phenobarbital and carbamazepine in epileptic patients: A preliminary neuropsychological report. Acta Neurol. Scand. 1986;74:59–62
  121. Gallassi R, Morreale A, Lorusso S, et al.  Cognitive effects of phenytoin during monotheraphy and after withdrawal. Acta Neurol. Scand. 1987;75:258–261
  122. Gallassi R, Morreale A, Lorusso S, et al.  Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch. Neurol. 1988;45:892–894
  123. Gallasi R, Morreale A, Lorusso S, et al.  Cognitive effects of valproate. Epilepsy Res. 1990;5:160–164
  124. Gallassi R, Morreale A, Di Sarro R, et al.  Cognitive effects of antiepileptic drug discontinuation. Epilepsia. 1992;33(Suppl. 6):S41–844
  125. Porter RJ. How to use antiepileptic drugs. In:  Levy RH,  Dreifuss FE,  Mattson RH editor. Antiepileptic Drugs. New York: Raven Press; 1989;p. 117–132
  126. Trimble MR. Cognitive effects of anticonvulsants [Letter]. Neurology. 1991;41:1326
  127. Thompson PJ. Comments on: ‘Differential effects of first antiepileptic drug application in lesional and non-lesional patients with epilepsy’. Seizure. 1993;2:311–313
  128. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: A meta-analysis. Neurology. 1994;44:601–608
  129. Ransom BR, Elmore JG. Effects of antiepileptic drugs on the developing central nervous system. In: 2nd edn..  Smith D,  Treiman D,  Trimble M editor. Advances in Neurology. Vol. 55:New York: Raven Press; 1991;p. 225–237
  130. Raju TNK, Langenberg P, Sen A. Suspended judgement. Treatment effect size in clinical trials: An example from surfactant trials. Control. Clin. Trials. 1993;14:467–470

PII: 0920-1211(95)00047-X

Epilepsy Research
Volume 22, Issue 2 , Pages 65-95 , October 1995

Article Tools